Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma

Head and Neck

Volumn 38, Issue 7, 2016, Pages 1074-1084

  Nguyen, Nghia ^a   Bellile, Emily ^b   Thomas, Daffyd ^a   McHugh, Jonathan ^a   Rozek, Laura ^b   Virani, Shama ^b   Peterson, Lisa ^b   Carey, Thomas E ^a   Walline, Heather ^a   Moyer, Jeffery ^a   Spector, Matthew ^a   Perim, Daniel ^a   Prince, Mark ^a   McLean, Scott ^a   Bradford, Carol R ^a   Taylor, Jeremy M G ^b   Wolf, Gregory T ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Cancer; Prognosis; Tumor infiltrating lymphocytes

Indexed keywords

CD4 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; T6 ANTIGEN; TRANSCRIPTION FACTOR FOXP3; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE SPECIFIC SURVIVAL; FEMALE; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HELPER CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LANGERHANS CELL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE; VERY ELDERLY; COHORT ANALYSIS; DISEASE FREE SURVIVAL; HEAD AND NECK TUMOR; IMMUNOLOGY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84959378098     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.24406     Document Type: Article

References (46)

1. Adams S, Gray RJ, Demaria S, et al., Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014; 32: 2959-2966.
2. Loi S, Sirtaine N, Piette F, et al., Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013; 31: 860-867.
3. Mahmoud SM, Paish EC, Powe DG, et al., Tumor-infiltrating CD8 + lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011; 29: 1949-1955.
4. Haas M, Dimmler A, Hohenberger W, Grabenbauer GG, Niedobitek G, Distel LV,. Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. BMC Gastroenterol 2009; 9: 65.
5. Angell H, Galon J,. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol 2013; 25: 261-267.
6. Wolf GT, Chepeha DB, Bellile E, et al., Tumor infiltrating lymphocytes (TIL) and prognosis in oral cavity squamous carcinoma: a preliminary study. Oral Oncol 2015; 51: 90-95.
7. Russell MA, Cooper AC, Dhayal S, Morgan NG,. Differential effects of interleukin-13 and interleukin-6 on Jak/STAT signaling and cell viability in pancreatic β-cells. Islets 2013; 5: 95-105.
8. Distel LV, Fickenscher R, Dietel K, et al., Tumour infiltrating lymphocytes in squamous cell carcinoma of the oro- and hypopharynx: prognostic impact may depend on type of treatment and stage of disease. Oral Oncol 2009; 45: e167-e174.
9. Pretscher D, Distel LV, Grabenbauer GG, Wittlinger M, Buettner M, Niedobitek G,. Distribution of immune cells in head and neck cancer: CD8 + T-cells and CD20 + B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma. BMC Cancer 2009; 9: 292.
10. Badoual C, Hans S, Rodriguez J, et al., Prognostic value of tumor-infiltrating CD4 + T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006; 12: 465-472.
11. Badoual C, Hans S, Merillon N, et al., PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013; 73: 128-138.
12. Berinstein NL, Wolf GT, Naylor PH, et al., Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen. Cancer Immunol Immunother 2012; 61: 771-782.
13. Balermpas P, Michel Y, Wagenblast J, et al., Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br J Cancer 2014; 110: 501-509.
14. Ward MJ, Thirdborough SM, Mellows T, et al., Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. Br J Cancer 2014; 110: 489-500.
15. Jung AC, Guihard S, Krugell S, et al., CD8-alpha T-cell infiltration in human papillomavirus-related oropharyngeal carcinoma correlates with improved patient prognosis. Int J Cancer 2013; 132: E26-E36.
16. Wansom D, Light E, Thomas D, et al., Infiltrating lymphocytes and human papillomavirus-16 - associated oropharyngeal cancer. Laryngoscope 2012; 122: 121-127.
17. Nordfors C, Grün N, Tertipis N, et al., CD8 + and CD4 + tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma. Eur J Cancer 2013; 49: 2522-2530.
18. Nocito A, Kononen J, Kallioniemi OP, Sauter G,. Tissue microarrays (TMAs) for high-throughput molecular pathology research. Int J Cancer 2001; 94: 1-5.
19. Goldman SA, Baker E, Weyant RJ, Clarke MR, Myers JN, Lotze MT,. Peritumoral CD1a-positive dendritic cells are associated with improved survival in patients with tongue carcinoma. Arch Otolaryngol Head Neck Surg 1998; 124: 641-646.
20. Colmone A, Li S, Wang CR,. Activating transcription factor/cAMP response element binding protein family member regulated transcription of CD1A. J Immunol 2006; 177: 7024-7032.
21. Gogolak P, Rethi B, Szatmari I, et al., Differentiation of CD1a- and CD1a + monocyte-derived dendritic cells is biased by lipid environment and PPARgamms. Blood 2007; 109: 643-652.
22. Yang H, Yang K, Khafagi A, et al., Sensitive detection of human papillomavirus in cervical, head/neck, and schistosomiasis-associated bladder malignancies. Proc Natl Acad Sci U S A 2005; 102: 7683-7688.
23. Kumar B, Cordell KG, Lee JS, et al., EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008; 26: 3128-3137.
24. Dewyer NA, Wolf GT, Light E, et al., Circulating CD4-positive lymphocyte levels as predictor of response to induction chemotherapy in patients with advanced laryngeal cancer. Head Neck 2014; 36: 9-14.
25. Anitei MG, Zeitoun G, Mlecnik B, et al., Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin Cancer Res 2014; 20: 1891-1899.
26. Fridman WH, Galon J, Pagès F, Tartour E, Sautès-Fridman C, Kroemer G,. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res 2011; 71: 5601-5605.
27. Ladoire S, Martin F, Ghiringhelli F,. Prognostic role of FOXP3 + regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother 2011; 60: 909-918.
28. Salama P, Phillips M, Grieu F, et al., Tumor-infiltrating FOXP3 + T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009; 27: 186-192.
29. deLeeuw RJ, Kost SE, Kakal J, Nelson BH,. The prognostic value of FoxP3 + tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res 2012; 18: 3022-3029.
30. Näsman A, Romanitan M, Nordfors C, et al., Tumor infiltrating CD8 + and Foxp3 + lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancer. PLoS One 2012; 7: e38711.
31. Sun DS, Zhao MQ, Xia M, Li L, Jiang YH,. The correlation between tumor-infiltrating Foxp3 + regulatory T cells and cyclooxygenase-2 expression and their association with recurrence in resected head and neck cancers. Med Oncol 2012; 29: 707-713.
32. Wolf GT, Hudson JL, Peterson KA, Miller HL, McClatchey KD,. Lymphocyte subpopulations infiltrating squamous carcinomas of the head and neck: correlations with extent of tumor and prognosis. Otolaryngol Head Neck Surg 1986; 95: 142-152.
33. Rajjoub S, Basha SR, Einhorn E, Cohen MC, Marvel DM, Sewell DA,. Prognostic significance of tumor-infiltrating lymphocytes in oropharyngeal cancer. Ear Nose Throat J 2007; 86: 506-511.
34. Brown JR, Wimberly H, Lannin DR, Nixon C, Rimm DL, Bossuyt V,. Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 2014; 20: 5995-6005.
35. Denkert C, Loibl S, Noske A, et al., Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28: 105-113.
36. Denkert C, von Minckwitz G, Brase JC, et al., Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol 2015; 33: 983-991.
37. Bradford CR, Kumar B, Bellile E, et al., Biomarkers in advanced larynx cancer. Laryngoscope 2014; 124: 179-187.
38. Lee AM, Clear AJ, Calaminici M, et al., Number of CD4 + cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 2006; 24: 5052-5059.
39. Galon J, Pagès F, Marincola FM, et al., Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012; 10: 205.
40. Miles FL, Sikes RA,. Insidious changes in stromal matrix fuel cancer progression. Mol Cancer Res 2014; 12: 297-312.
41. Whiteside TL,. Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression? Cancer Immunol Immunother 2014; 63: 67-72.
42. Iuchi T, Teitz-Tennenbaum S, Huang J, et al., Interleukin-21 augments the efficacy of T-cell therapy by eliciting concurrent cellular and humoral responses. Cancer Res 2008; 68: 4431-4441.
43. Woodford D, Johnson SD, De Costa AM, Young MR,. An inflammatory cytokine milieu is prominent in premalignant oral lesions, but subsides when lesions progress to squamous cell carcinoma. J Clin Cell Immunol 2014; 5: 230.
44. Oshimori N, Oristian D, Fuchs E,. TGF-β promotes heterogeneity and drug resistance in squamous cell carcinoma. Cell 2015; 160: 963-976.
45. Postow MA, Callahan MK, Wolchok JD,. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015; 33: 1974-1982.
46. Li Q, Lao X, Pan Q, et al., Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin Cancer Res 2011; 17: 4987-4995.